• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Seagen Inc. - Common Stock (NQ:SGEN)

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 13, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Seagen Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
News headline image
Six-Year Overall Survival Results Added to U.S. Prescribing Information for ADCETRIS® (brentuximab vedotin) as First-Line Treatment for Advanced Hodgkin Lymphoma
June 14, 2023
From Seagen Inc.
Via Business Wire
News headline image
Investor Opportunities Ahead of Clinical Updates, Says Analyst Initiating Coverage on Ambrx Biopharma with 'Buy' Rating ↗
June 14, 2023
B Riley Securities has initiated Ambrx Biopharma Inc (NASDAQ: AMAM) with a Buy rating and a  
Via Benzinga
News headline image
Seagen's Adcetris/Immunotherapy Combo Achieves 98% Overall Response Rate in Early-Stage Lymphoma Setting ↗
June 13, 2023
Seagen Inc (NASDAQ: SGEN) announced updated efficacy and safety results from Part C of phase 2 single-arm trial of Adcetris (brentuximab vedotin) combined with nivolumab and standard chemotherapy... 
Via Benzinga
News headline image
Seagen Announces ADCETRIS® (brentuximab vedotin) Plus Novel Immunotherapy Combination Delivers 98% Overall Response Rate and 93% Complete Response Rate in Patients with Early-Stage Classical Hodgkin Lymphoma (cHL)
June 13, 2023
From Seagen Inc.
Via Business Wire
News headline image
If You Invested $1000 In This Stock 10 Years Ago, You Would Have $5,800 Today ↗
June 07, 2023
 
Via Benzinga
News headline image
$100 Invested In This Stock 20 Years Ago Would Be Worth $4,000 Today ↗
May 23, 2023
 
Via Benzinga
News headline image
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree ↗
June 02, 2023
Big Pharma is facing a patent cliff that could siphon off billions in revenue. 
Via Investor's Business Daily
News headline image
3 Undervalued Biotech Stocks to Buy Before They Blast Off ↗
June 02, 2023
Fundamental analysis makes these three undervalued biotech stocks to buy plus they have other catalysts that make them compelling. 
Via InvestorPlace
News headline image
3 Stocks Worth Buying at 52-Week Lows
May 30, 2023
Here are three stocks that are trading near their 52-week lows and may be primed for a short-term rally for opportunistic investors 
Via MarketBeat
News headline image
Seagen Stockholders Approve Acquisition by Pfizer
May 30, 2023
From Seagen Inc.
Via Business Wire
News headline image
Check Out What Whales Are Doing With SGEN ↗
May 18, 2023
 
Via Benzinga
News headline image
(SGEN) - Analyzing Seagen's Short Interest ↗
May 15, 2023
 
Via Benzinga
News headline image
$100 Invested In Seagen 5 Years Ago Would Be Worth This Much Today ↗
May 05, 2023
 
Via Benzinga
News headline image
FTC Wants to Block the Amgen-Horizon Deal: Is Pfizer's Acquisition of Seagen at Risk, Too? ↗
May 24, 2023
Should Pfizer and Seagen investors be worried? 
Via The Motley Fool
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
May 23, 2023
 
Via Benzinga
News headline image
Pfizer Just Took Out $31 Billion in Debt. Here's Why That's Good News ↗
May 22, 2023
The pharmaceutical giant wouldn't be borrowing if it didn't have plans for how to make a tidy return. 
Via The Motley Fool
News headline image
Is Pfizer's Seagen Deal In Jeopardy Amid Antitrust Scrutiny?
May 19, 2023
Despite worries about FTC scrutiny, Pfizer remains optimistic about its planned Seagen acquisition, issuing $31 billion in bonds to finance the deal. 
Via MarketBeat
Topics Bonds
News headline image
FDA Signals Support For Pfizer's Maternal RSV Shot Ahead Of Adcomm, Pfizer Raises $31B In Debt To Fund Seagen Deal ↗
May 17, 2023
Pfizer Inc (NYSE: PFE) plans to raise $31 billion from a debt offering to finance its proposed acquisition of Seagen Inc (NASDAQ: SGEN)  
Via Benzinga
News headline image
Seagen's Return on Invested Capital Insights ↗
May 03, 2023
 
Via Benzinga
News headline image
FTC Files Lawsuit To Stop Amgen Buying Horizon Therapeutics, Sending Shockwaves Through Biopharma M&A ↗
May 16, 2023
In a rare move to block a large pharma deal, the U.S. 
Via Benzinga
News headline image
GDC Stock Alert: Why Is GD Culture Group Up 106% Today? ↗
May 16, 2023
GD Culture (GDC) stock is rocketing higher on Tuesday with investors reacting to the company's earnings report for Q1 2023. 
Via InvestorPlace
News headline image
Why Is Guardforce AI (GFAI) Stock Up Today? ↗
May 16, 2023
Guardforce AI (GFAI) stock is on the rise Tuesday after the AI company announced the closing of a public share offering. 
Via InvestorPlace
News headline image
GILD Stock Price Predictions: Is Gilead Sciences Really Worth $100? ↗
May 16, 2023
Gilead Sciences (GILD) stock is a hot topic on Tuesday as a new price target predicts a roughly 28% upside for the shares. 
Via InvestorPlace
News headline image
Seagen (SGEN) Stock Falls 6% After Director Sells Shares ↗
May 16, 2023
Seagen (SGEN) stock is slipping on Tuesday after one of the company's directors sold shares worth more than $372,000 on Monday. 
Via InvestorPlace
News headline image
Horizon Tumbles — Taking Seagen, Prometheus With It — On Reports FTC Could Block Its Amgen Takeover ↗
May 16, 2023
Reports the FTC could block Amgen's takeover of Horizon reverberated across biotechs on Tuesday, with HZNP stock's crash leading the way. 
Via Investor's Business Daily
News headline image
Vaccine Sales Are Falling. Should You Still Buy Pfizer? ↗
May 04, 2023
This is a transition year for Pfizer. 
Via The Motley Fool
News headline image
7 High-Yield Dividend Stocks to Buy and Hold Forever ↗
April 30, 2023
A stagnant market can be frustrating, but also a good time to look for high-yield dividend stocks to buy now. 
Via InvestorPlace
News headline image
Could Government Drug-Price Negotiations Sound The Death Knell For Biotech Stocks? ↗
April 28, 2023
Experts fear a change in how Medicare buys drugs could slam biotech and pharma companies. 
Via Investor's Business Daily
News headline image
Seagen Reports First Quarter 2023 Financial Results
April 27, 2023
From Seagen Inc.
Via Business Wire
News headline image
Earnings Scheduled For April 27, 2023 ↗
April 27, 2023
Companies Reporting Before The Bell • Cazoo Gr (NYSE:CZOO) is expected to report earnings for its first quarter. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap